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ABSTRACT: In recent years, atmospheric cold plasma (ACP) has been widely investigated for
potential application as an alternative decontamination technology in biomedical and healthcare
sectors. In this study, the antimicrobial efficacy of ACP against Pseudomonas aeruginosa biofilms
was investigated. The 48-h biofilms were treated inside sealed polypropylene containers with a
high-voltage dielectric barrier discharge (DBD) ACP (80 kVRMS) and subsequently stored for 24
h at room temperature. Treatment for 60 s by either the direct or indirect mode of ACP exposure
(inside or outside plasma discharge, respectively) reduced bacterial populations by an average of
5.4 log cycles from an initial 6.6 log10 CFU/mL. Increasing the treatment time from 60 s to 120 s
and 300 s reduced biofilms to undetectable levels. According to XTT assay (a metabolic activity
assay), an extended treatment time of 300 s was necessary to reduce metabolic activity of cells in
biofilms by an average of 70%. Further investigation of biofilm viability by confocal laser scanning microscopy (CLSM) and scanning electron microscopy (SEM) demonstrated that extended
ACP treatment had a detrimental effect on the viability of P. aeruginosa through disintegration of
both bacterial cells and the biofilm matrix. The results of this study demonstrate the potential of
a novel, in-package, high-voltage ACP decontamination approach for the inactivation of bacterial
biofilms.
KEY WORDS: Atmospheric cold plasma, Pseudomonas aeruginosa, biofilm, CLSM, SEM

I. INTRODUCTION
Pseudomonas aeruginosa is one of the most abundant microorganisms in the natural
environment and is a common opportunistic nosocomial pathogen, which causes a wide
variety of acute and persistent infections in immunocompromised patients. This microorganism has become increasingly important due to associated prevalence, pathogenicity, and increasing resistance to antimicrobial treatments, causing morbidity and
mortality.1–2 Pseudomonas associated health care infections include respiratory tract
infections,3–4 urinary tract infections,5 surgical and burn wound infections6,7 and bloodstream infections.8,9 According to Neonatal Infection Surveillance Network, between
2005 and 2011, in the United Kingdom, Pseudomonas spp. were responsible for 93% of
neonatal infection outbreaks and with 18% of associated deaths.10
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Water is the main environmental reservoir of P. aeruginosa, and the water distribution system is one of the possible sources of P. aeruginosa in healthcare settings
(taps, sinks, etc.).2,11 In addition, P. aeruginosa has a tendency to form biofilms. Recently, Walker et al.12 demonstrated that, within hospital facilities in Northern Ireland,
P. aeruginosa exists predominantly in the form of biofilm in water tap outlets, which
are therefore a possible cause of infection. Biofilms are broadly described as a microbially derived sessile community with altered phenotype with respect to growth rate,
in which cells are attached to a substratum or to each other and are embedded in a matrix of extracellular polymeric substances (EPSs).13 Material secreted by bacteria EPS
(i.e., polysaccharides, proteins, lipids, and nucleic acids) act as a complex defensive
mechanism protecting bacteria from unfavourable environmental conditions. Due to
the heterogeneous nature and multiple mechanisms of resistance, biofilms have an
enormous impact on medicine.14 It has been estimated that up to 80% of human bacterial infections are associated with biofilms.15 Once biofilms are established, different
mechanisms account for resistance to antimicrobial treatments. In addition, inappropriate use or overuse of antibiotics may also result in increased bacterial resistance.16,17
Therefore, alternative antimicrobial measures are required as a key component of the
prevention of healthcare-associated infections (HAIs) to ensure effective reductions
and elimination of pathogens and their associated biofilms while simultaneously
averting bacterial resistance.
Atmospheric cold plasma (ACP) technology is an innovative field that is intensively
researched for a range of different medical applications. Von Woedtke et al.18 classified plasma for medical application according to two general principles: indirect use of
plasma to treat surfaces, materials, or devices for medical applications, and application
of physical plasma on or within the human body. Sterilization of medical materials or
devices (e.g., medical implants, catheters, or materials in blood purification systems) is
the main use of indirect plasmas for medical purposes;20 whereas physical plasmas are
under intense study for applications in wound healing,19,20 blood coagulation and skin
regeneration,21 dentistry,22 and apoptosis of cancer cells.23
To date, research on ACP sterilization has demonstrated effective reduction of clinically important microorganisms in their planktonic state or in biofilms.24,25 However, the
antimicrobial effects of plasma were reduced against biofilms by comparison with their
planktonic counterparts.26–27
The aim of this study was to evaluate the potential of novel, in-package, high-voltage air DBD ACP for elimination of P. aeruginosa biofilm. The effects of treatment time
and mode of plasma exposure were investigated. Surviving bacterial populations in biofilm were estimated by colony count and XTT (2,3-bis (2-methoxy-4-nitro-5-sulfophenyl) [phenyl-amino)car-bonyl]-2H-tetrazolium hydroxide) assays for determination of
cell viability and metabolic activity, respectively. The ability of the contained ACP reactive species to penetrate complex biofilm structures was observed using a LIVE/DEAD
bacterial viability kit followed by confocal scanning laser microscopy (CSLM). Scanning electron microscopy (SEM) was conducted to observe morphological changes of
biofilms caused by ACP treatment.
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II. MATERIALS AND METHODS
A. Bacterial Strains and Inocula Preparation
Pseudomonas aeruginosa ATCC 27853, a blood culture isolate, was obtained from the
microbiology stock culture of the School of Food Science and Environmental Health of
the Dublin Institute of Technology and was utilized in all experiments. A single isolated
colony of the culture was inoculated in tryptic soy broth without glucose [TSB (-G),
ScharlauChemie, Spain] and was incubated at 37°C for 18 h. The overnight culture was
diluted in TSB to a density of 7.0 log10 colony-forming units per milliliter (CFU/mL),
using the McFarland standard. This bacterial cell concentration was further used as an
inoculum for biofilm formation.
B. Biofilm Formation
Bacterial biofilms were produced in either 96-well plates for the colony count and XTT
assay, on glass coverslips (24 x 32 mm) for CLSM analysis, or using tissue culture-treated inserts containing polycarbonate membrane (0.45 µm, Millicell, Millipore, Ireland)
for SEM analysis. Biofilms in the 96-well plates were obtained by adding 200 µl of TSB
bacterial suspension (7.0 log10 CFU/ml) to the wells of the plates. For production of biofilms for CLSM, coverslips were positioned inside the wells of the 6-well culture plate,
and 8 ml of TSB bacterial suspension was added. For production of biofilms on polycarbonate membranes, inserts were placed inside the wells of the 6-well plate, which were
filled with 2 ml of TSB bacterial suspension. The plates were incubated at 37°C for 48
h. After 24 h of incubation, the supernatant from each well of the 96-well and 6-well
plates containing inserts or glass coverslips was replaced with fresh TSB, with further
incubation for 24 h. After incubation, the TSB containing suspended bacterial cells was
removed and the wells were extensively rinsed with sterile PBS, leaving only bacterial
biofilms for further investigation. Negative controls were obtained using TSB without
inocula. Prior to each experiment, the biofilms were air dried for 60 min.
C. Experimental Design
The ACP system utilized a high-voltage DBD system previously described in Ziuzina et
al.28 with a maximum voltage output of 120 kV at 50 Hz. The distance between the two
15-cm diameter aluminium disk electrodes was 22 mm, which was equal to the height of
the polypropylene container (310 x 230 x 22 mm) utilized as both a sample holder and
as a dielectric barrier. For this study, ACP was generated in air at 80 kVRMS.
The 96-well plates, glass coverslips or membrane inserts containing biofilms were
placed in the center of the plastic container directly between the electrodes within the
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plasma discharge for direct plasma treatment (Fig. 1A). For indirect plasma treatment,
a separate container was used, and either substrate containing biofilm was placed to
achieve treatment outside the plasma discharge (Fig. 1B). After sample loading, each
container was sealed with a high-barrier polypropylene bag (Cryovac, B2630, USA) and
placed between the aluminium electrodes of the transformer. The biofilms were treated
with direct/indirect ACP for 0, 60 s, 120 s, and 300 s and were subjected to a post-treatment storage for 24 h at room temperature. Control samples were untreated. All experiments involving biofilm formation in 96-well plates were conducted using three independently grown cultures and were repeated at least twice. Experiments were repeated
three times when biofilms were grown on glass coverslips and membrane inserts.

FIG. 1: Schematic diagram of samples distributed within polypropylene container with respect
to the electrodes: (a) direct treatment and (b) indirect treatment
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D. Biofilm Assays
1. Crystal violet assay (CV)
Crystal violet (CV) staining was used to monitor biofilm formation capacity using 24
h and 48 h incubation times. Biofilm mass was quantified as described previously.29
The absorbance was measured at 590 nm on a microplate reader (Synergy HT, Biotek
Instruments, Inc.). Each absorbance value was corrected by subtracting the means of
absorbance of a blank (uninoculated) TSB. Experiments were carried out in triplicate
and were repeated at least twice.
2. Colony count assay
Following ACP treatment and 24 h post treatment storage, 200 µl of sterile PBS was
added into the biofilm containing wells of the 96-well plate. To disrupt biofilms, the
plates were sonicated using a water table sonicator (Bransonic 5510E-MT, Branson,
USA) for 5 min. Suspensions were pooled together from the wells into sterile Eppendorf
tubes, serially diluted in maximum recovery diluent (MRD, ScharlauChemie, Spain), if
necessary, and 0.1-mL aliquots of appropriate dilutions were surface plated on TSA and
incubated at 37°C for 24 h. Results are presented as surviving bacterial population in
log10 CFU/mL units.
3. XTT assay
Prior to each assay, fresh solution of 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl) [phenyl-amino)car-bonyl]-2H-tetrazolium hydroxide (XTT, 1 mg/ml, Sigma-Aldrich, Ireland) was prepared as described previously.32 The wells containing biofilms and negative
controls (TSB without inocula) were filled with sterile PBS (100 µl), then XTT-menadione (100 µl) was added to all wells. Plates were incubated for 5 h at 37°C in the dark.
After incubation, the supernatant (100 µl) from each well was transferred into the wells
of a new 96-well microtiter plate, and the absorbance was measured at 486 nm on a microplate reader. The percentage of the surviving bacterial population was calculated as
((AACP - AC) / A0) × 100%, where AACP, AC, and A0 are the absorbance of ACP treated, the
negative control, and untreated control biofilms, respectively.
4. Confocal laser scanning microscopy (CLSM)
Prior to analysis, to differentiate viable and dead bacteria, untreated controls and biofilms
treated with either direct or indirect ACP for 300 s were stained using a LIVE/DEAD
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bacterial viability kit containing SYTO9 and propidium iodide (PI) (Sigma-Aldrich,
Ireland). Biofilms grown on glass coverslips were covered with 200 µL of SYTO9,
and the PI solution was prepared according to the manufacturer’s instructions and was
incubated for 15 min in the dark. The samples were rinsed with sterile deionized water,
placed on the microscope glass slide, and imaged using a Zeiss confocal microscope
(Carl Zeiss, Model: LSM 510, Germany). The quantitative parameters to characterize
biofilm thickness were obtained from CLSM stack images and the sample images were
further analyzed by IMARIS image analysis software (Bitplane, Inc.). The maximum
thickness of the biofilm was determined from the value of the Y-axis.
5. Scanning electron microscopy (SEM)
For SEM analysis, untreated controls and P. aeruginosa biofilms treated directly or indirectly with ACP for 300 s were selected and prepared as described by Gratao et al.,30
with minor modifications. The cells were fixed in ice-cold 2.5% glutaraldehyde in 0.05
M sodium cacodylate buffer (pH 7.4) (SCB) for 2 h. The cells were washed with the
same buffer three times and were then fixed in 1% osmium tetroxide for 2 h at 4°C. After 2 h of fixation, bacterial cells were washed with SCB followed by three washes with
distilled water. The samples were treated using increasing concentrations of ethanol
(30%, 50%, 70%, 80%, 95%, and 99.5%) and dehydrated as described by Srey et al.31
using 33%, 50%, 66%, and 100% (v/v) hexamethyldisilazane (Sigma-Aldrich, Ireland).
To prevent surface charging by the electron beam, the samples were sputter-coated with
gold particles using Emitech K575X Sputter Coating Unit resulting in a coating of 10
nm after 30 s. The samples were examined visually using a FEI Quanta 3D FEG Dual
Beam SEM (FEI Ltd, Hillsboro, USA) at 5 kV.
E. Statistical Analysis
Statistical analyses were performed using SPSS 19.0 (SPSS, Inc., Chicago, USA). The
surviving populations of P. aeruginosa biofilms following ACP treatments were compared using analysis of variance (ANOVA). Means were compared according to the
method of Fisher’s least significant difference (LSD) at the 0.05 level.
III. RESULTS
A. Evaluation of Biofilm Biomass by CV Assay
According to the scheme described by Stepanovic et al.,32 24-h- and 48-h-old P. aeruginosa demonstrated strong ability to produce biofilms (Fig. 2A). Notably, after 48 h of
incubation, P. aeruginosa biofilms were clearly visible on the surface of the wells of the
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96-well microtiter plate (Fig. 2B). Based on these results, only bacterial biofilms grown
for 48 h were used in further studies aimed at investigating the efficacy of ACP to inactivate bacteria in not only the realistic but also the more resistant biofilm form.
B. Effects of ACP on P. aeruginosa biofilms Assessed by Colony Count
and XTT Assays
The influence of ACP treatment time and mode of exposure on viability of P. aeruginosa
biofilms based on colony count assay is presented in Fig. 3A. Generally, both direct and
indirect modes of plasma exposure effectively reduced bacterial populations in biofilms
after short treatment times. Prior to ACP treatment, an average population of bacterial
biofilm attached on the surface of the wells was 6.6 log10 CFU/mL. ACP treatment for 60
s reduced bacterial cells by an average of 5.4 log10 CFU/mL; increasing treatment time to
120 s and 300 s reduced the numbers of viable cells within the biofilms to levels below
detection limits (1.0 log10 CFU/mL).

FIG. 2: (a) P. aeruginosa biofilm formation evaluated by CV assay after 24 h and 48 h of incubation at 37°C; (b) P. aeruginosa biofilm formed in the wells of a 96-well microtiter plate. Top
row: uninoculated control wells. Bottom row: 48-h biofilm (yellow arrows)
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FIG. 3: (a) Surviving populations of P. aeruginosa 48-h biofilms assessed by colony count assay: untreated control biofilms (∆) after direct (◊) and indirect (□) ACP treatment. Vertical bars
represent standard deviation. Limit of detection, 1.0 log10 CFU/sample (b) Percentage surviving
populations of P. aeruginosa 48-h biofilms assessed by XTT assay: untreated control biofilms
(∆), after direct (◊) and indirect (□) ACP treatment. Vertical bars represent standard deviation

Percentage survival of P. aeruginosa biofilm after ACP exposure based on XTT
assay is presented in Fig. 3B. XTT absorbance values demonstrated that 60 s of direct
and indirect treatment reduced metabolic activity of cells by 37% and 49%, respectively.
Increasing treatment time from 60 s to 120 s further reduced cell metabolic activity by
63% and 70% when exposed to direct and indirect treatment, respectively. However, no
further reductions were observed by applying extended treatment time of 300 s, with a
maximum average reduction of 70% recorded. Notably, post treatment storage time of
24 h had a minor effect on biofilm activity for this microorganism based on both colony
count and XTT assays.
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C. Confocal Laser Scanning Microscopy (CLSM)
To evaluate the effect of ACP on viability of bacterial cells embedded in biofilm structures, CLSM analysis of untreated control and P. aeruginosa biofilms treated directly/
indirectly for 300 s was conducted. This analysis utilizes the mixture of SYTO9 (green
fluorescent) and PI (red fluorescent) nucleic acid dyes. SYTO9 labels bacterial cells
with both intact and damaged membrane, whereas PI penetrates only cells with damaged membrane. Therefore, this analysis allows determination of bacterial viability and
cell membrane integrity on the basis of different colors, where green and red represent
live and dead cells, respectively. The results of the CLSM analysis are presented in
Fig. 4. As can be seen from Fig. 4A, the untreated control sample exhibited completely
green fluorescence, i.e., only live cells were present. Maximum biofilm thickness of
23 µm was recorded. Confocal images of biofilms treated with either direct or indirect
ACP (Fig. 4B, 4C, respectively) displayed only red fluorescence, with no viable cells
remaining after treatment. Moreover, images of ACP-treated samples also indicated a
substantial reduction of biofilm thickness when compared with control biofilms. The
thickness of biofilms was reduced to 8 µm and 6 µm after direct and indirect ACP treatment, respectively.
D. Scanning Electron Microscopy (SEM)
To examine the effects of ACP on P. aeruginosa biofilm distribution and morphology,
SEM analysis of untreated control and samples treated directly or indirectly for 300 s
was conducted. Figure 5A represents untreated controls, in which clustered rod-shaped
bacterial cells are interconnected with each other by the complex biofilm matrix components. Significant damage of bacterial cells and EPS was observed after both direct

FIG. 4: CLSM images of P. aeruginosa 48-h biofilm stained with LIVE/DEAD bacterial viability kit: (a) untreated control; (b) 300 s of direct ACP treatment; (c) 300 s of indirect ACP
treatment. Cells stained green are alive and cells stained red are dead
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FIG. 5: SEM images of P. aeruginosa 48-h biofilm: (a) untreated control; (b) 300 s of direct ACP
treatment; (c) 300 s of indirect ACP treatment

and indirect ACP treatments. Complete disintegration of cells and biofilm matrix was
noted after direct ACP treatment: biofilms were converted into the ‘sponge-like,’ irregularly shaped debris compared with untreated controls (Fig. 5B). Although indirect ACP
had similar destructive effects on biofilm structures, small fractions of EPS components
were still detected after the treatment (Fig. 5C).
IV. DISCUSSION
In recent years, cold atmospheric plasma (ACP) has been widely investigated as an alternative sterilization technology for potential application in medicine. This technology
has been demonstrated to have great bactericidal effects against a wide range of microorganisms with high potential to avoid any thermal damage to both living and non-living biomedical structures.33 Our previous studies demonstrated that high-voltage DBD
ACP in conjunction with treatment of contaminated objects inside sealed packages and
following post treatment storage was very effective for inactivation of bacteria in their
planktonic form, reducing the numbers within seconds.31 However, bacterial biofilms,
as a predominant mode of microbial growth,34 represent major challenges in industrial
and health care settings due to their increased mechanical stability and antimicrobial
resistance.35 Therefore, in the present study, the potential of ACP to inactivate bacterial
pathogens was investigated against challenge P. aeruginosa biofilms, as one of the major causes of healthcare-associated infections.
P. aeruginosa is considered a model microorganism for biofilm research due to its
excellent ability to form biofilm.36 Because bacteria in older biofilms are more resistant
to antimicrobial treatments,37,38 only biofilms grown for 48 h were utilized to present
a realistic challenge to the ACP treatment. The effect of ACP treatment on P. aeruginosa biofilms was investigated utilizing widely accepted plate-count and XTT assays.
According to the results obtained from both assays, no significant difference between
the effects of direct and indirect modes of exposure on bacterial biofilms was found.
According to colony counts, rapid inactivation of cells in biofilm was achieved after
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relatively short treatments (60 s), resulting in reduction of bacterial levels by 5.4 log10
CFU/ml. With lower inactivation rates, however, bacterial populations were below detection limits after exposure to 120 s and 300 s of treatment. Similarly, Alkawareek et
al.39 reported biphasic reductions of P. aeruginosa biofilms due to ACP treatment, where
initial 60 s of plasma treatment resulted in rapid decline in bacterial levels, causing
slower reduction between 60 s and 240 s of treatment. In general, our data suggest that
80kV air in-package DBD ACP treatment exhibits considerably high inactivation potential against the most abundant and resistant bacterial form—biofilm. Notably, based
on our preliminary data, treatment for only 30 s was required to completely eliminate P.
aeruginosa (~7.0 log10 CFU/ml reduction) in the planktonic form (data not shown). In
general, according to previous reports, focusing on inactivation efficacy of ACP against
biofilm, complete inactivation of P. aeruginosa biofilm could be achieved after longer
treatment times, from 5 to 10 min.27,40 Utilization of different ACP systems and different
approaches to biofilm formation are probably the main reasons for variations in the published reports, which reduces the possibility of drawing adequate conclusions regarding
the overall plasma treatment effectiveness against bacterial biofilms. Comprehensive
system, process, and target comparative studies are still required.
To examine the effects of ACP on the metabolic state of P. aeruginosa biofilms, the
XTT assay was utilized, which involves intracellular reduction of XTT to a water-soluble formazan, the absorbance of which is proportional to the number of metabolically
active bacterial cells.32 This method has been successfully utilized to measure the respiratory activity of bacteria after application of different sanitizers as well as ACP.27,41
According to the results obtained from the XTT assay, even after extended treatment
time of 300 s, an average of 30% of cells in biofilms were still metabolically active. This
outcome was also observed by Alkawareek et al.,42 who reported that ACP inactivated
85% of P. aeruginosa cells according to colony counts, while the XTT absorbance value
corresponded to 36%. Borges et al.42 observed similar bacterial response to stress, when
P. aeruginosa biofilm was subjected to naturally derived compounds with 30% of cell
metabolic activity remaining after the treatment. In general, the plate count assay accounts only for culturable bacterial cells and does not take into account cells that might
still be metabolically active. Bacteria that fail to grow on the bacteriological media
but are still alive are described as a viable but nonculturable (VBNC) state of bacteria.
This result has been demonstrated for many microorganisms when facing environmental
stress, including P. aeruginosa.43,44 Bacteria in a VBNC state can regain culturability and
can retain virulence, even when they are in the nonculturable state. Therefore, VBNC
bacteria may contribute to further contamination.45
CLSM, in conjunction with nucleic acid dyes SYTO9 and PI, was used to evaluate the effects of ACP treatment on viability and cell membrane integrity. Microscopic
observations demonstrated that the bacterial cell membrane was completely ruptured
following treatment, which indicates the potential destruction abilities of the high-voltage system used. Although high sterilization potential is among the main characteristics
and advantages of every antimicrobial technique, physical removal of bacterial biofilms
is another important criteria that is gaining increased attention, specifically in plasma
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biofilm research. Confocal microscopy analysis also demonstrated that ACP treatment
was able not only to successfully inactivate cells through penetration inside complex
bacterial aggregates but also to substantially remove the biofilm from the associated
surface, which was identified by measuring the biofilm thickness.
The results of this work also point to the complex interaction between reactive species generated by air plasma and biofilms. As is commonly known, air plasma is an
excellent source of electrons and positive and negative ions, free radicals, stable conversion products (e.g., ozone), excited atoms and molecules, and ultraviolet radiation
photons.46 The main mechanism of action of ACP reactive species is the diffusion of
oxygen species through the bacteria cell wall, which causes local damage to the cytoplasmic membrane, protein and DNA strands, as well as physical effects by causing microbial etching and erosion.47,48 In this study, to monitor the physical changes caused by
ACP treatment, SEM analysis of biofilms was conducted. The microscopic images enabled observation of the differences between control (untreated) samples, which proved
biofilm complexity and the resulting challenge linked to antimicrobial resistance, and
treated samples, where cells and biofilm components were significantly damaged by the
action of ACP.
Notably, the in-package, high-voltage ACP treatment used a 24-h post treatment
storage time. This allowed the retention of plasma reactive species inside the pack over
time, thus facilitating bactericidal action of these species on biofilm samples. This approach is more likely to show increased antimicrobial effects of plasma, the mechanism
of which is mainly based on the reaction of long-lived and recombined species rather
than on charged particles or short-lived species, which are more relevant to effects noted
using treatment without post treatment storage. This approach could contribute to an
increased potential of plasma species to penetrate complex biofilm matrices further inactivating the cells. However, there are several limitations in this work. It is known that
formation of biofilms is influenced by environmental conditions and characteristics of
substrates to which bacteria attach. In this study, the model system, a 96-well microtiter
plate, was utilized for biofilm development, which cannot holistically describe the broad
range of materials implicated in biofilm formation within clinical environments. Moreover, it is more likely that, in real clinical environments, biofilm communities may be
inhabited by numerous different species and that interactions among these species could
contribute to the organization of multispecies biofilms. Multispecies biofilms are usually
more resistant against antimicrobial treatments than monospecies biofilms.49 Therefore,
further studies on the efficacy of ACP against multispecies biofilms developed on a wider range of relevant materials may be warranted.
IV. CONCLUSION
The results of this study clearly demonstrate that in-package, high-voltage air DBD ACP
in conjunction with post treatment storage is very effective against complex bacterial
biofilms. With relatively short treatment of 60 s, it was possible to achieve substantial
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reductions (5.4 log10 CFU/ml) of 48-h-old P. aeruginosa biofilms. In this study, a series
of methods were utilized to monitor the changes in biofilms caused by ACP treatment,
namely, colony count, XTT assay, CLSM, and SEM, elucidating information regarding
different parameters associated with the viability of cells in biofilms. In terms of metabolic activity, 30% of cells survived extended treatment for 300 s, whereas, according
to colony count, there were no bacterial survivors. These results indicate a possible induction of VBNC state of bacteria due to the stress caused by ACP treatment. However,
CLSM and SEM analyses indicate that extended treatment caused severe damage to P.
aeruginosa cell membranes and effectively disrupted heterogeneous biofilm structures.
However, better understanding of interactions between plasma ACP reactive species
and biofilm components and identification of specific biofilm targets will allow further
optimization of ACP treatment parameters toward more effective and less damaging
sterilization required in the field of medicine.
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